Porcine Circovirus 3
LEVELS: Highly unlikely; No human illness; Already in the herd; Laboratory-dependent; Minor; Negligible; Little; Needed but not available
| Register id | pcv3 |
| Type | virus |
| Scientific name | Porcine circovirus 3 |
| NCBI taxid | 1868221 |
| Evidence | 2 document(s) |
| Assigned | 2026-09-06, against criteria version 093366e352a2 |
Overview
Porcine circovirus 3 was discovered by next-generation sequencing and has since been found worldwide in both healthy and diseased pigs. It is considered pathogenic, and case definitions have been proposed for two conditions: PCV3 reproductive disease — late-term abortions and stillbirths — and, less consistently, a systemic wasting disease in postweaning pigs. The characteristic lesion is inflammation of the blood vessels, together with changes in the heart, lungs and kidneys. The strongest evidence is experimental: pregnant gilts inoculated at various stages of gestation produced fetuses with high viral loads and matching lesions, and piglets infected before their immune systems matured were born with lesions already present, which raises the possibility that the postweaning disease is a delayed consequence of infection in the uterus. Because the virus is everywhere, finding it proves nothing; a diagnosis requires the clinical signs, the vascular lesions, and the virus demonstrated within those lesions. Research has been slowed by a shortage of isolates and of virus-free pigs to work with. It is shed in oral fluids, nasal secretions and faeces, passes vertically and in colostrum, and is common in feral swine, with transmission from wild boar to domestic pigs demonstrated in Italy. There is no vaccine, and PCV2 vaccination gives no cross-protection.
C1 Zoonotic potential
Likelihood of transmission from pigs to humans
Highly unlikely: Human infection with the agent has never been reported, or has been reported but is not attributed to pig or pork exposure
Basis. ch27 27.3, the whole Public Health section for the chapter: "PCVS ARE NOT ZOONOTIC... PCV2 AND PCV3 HAVE BEEN DETECTED IN OTHER SPECIES BESIDES SUIDS, BUT NOT IN HUMANS." 27.4 lists where PCV3 DNA has turned up outside pigs -- rodents, warthogs, dogs, domestic and wild ruminants including chamois, red and roe deer, and ticks taken off PCV3-negative roe deer -- and warns that "PCV DETECTION IN THESE SPECIES IS EXTREMELY SPORADIC and the demonstration of a productive infection, as opposed to contamination or passive exposure (e.g. environment, feed), is challenging". Humans appear on none of those lists. shic_2026_pcv3: "Porcine circoviruses (PCVs), including PCV3, are not considered to be zoonotic."
How this level was decided
Level 1, and the statement is explicit rather than inferred: the chapter names PCV3 alongside PCV2 as having been looked for in other species and found in several, humans excluded. NOTE THAT PCV3 HAS BEEN SEQUENCED OUT OF A WIDER HOST RANGE THAN PCV2 -- deer, chamois, dogs, rodents, even ticks -- which makes the absence from people informative rather than untested. The chapter's own caution applies to all of it: finding viral DNA in a species is not evidence of infection in that species. Level 1 confirmed.
C2 Zoonotic impact
Severity of human illness caused by the agent
No human illness: Agent does not cause illness in people
Basis. ch27 27.3, the whole Public Health section for the chapter: "PCVS ARE NOT ZOONOTIC... PCV2 AND PCV3 HAVE BEEN DETECTED IN OTHER SPECIES BESIDES SUIDS, BUT NOT IN HUMANS." shic_2026_pcv3: "Porcine circoviruses (PCVs), including PCV3, are not considered to be zoonotic."
How this level was decided
Level 1. C2 grades the severity of illness acquired from pigs, and the chapter says the genus does not infect people. C1L1 implies C2L1, which validate_criteria.py checks. Level 1 confirmed.
C3 Herd introduction risk
Effort required to keep the agent out of the herd
Already in the herd: Present in most herds, or carried by pigs themselves, so there is no introduction event to prevent
Basis. ch27 27.1: "since its discovery by next-generation sequencing, THE VIRUS HAS BEEN DETECTED WORLDWIDE IN BOTH HEALTHY AND DISEASED PIGS." 27.4: "PCV1, PCV2, and PCV3 are commonly detected in FERAL SWINE, OFTEN AT HIGH PREVALENCE, ESPECIALLY PCV3. The close genetic relationship between strains collected from domestic and wild subjects suggests that the exchange of virus between these populations is common", and "the transmission of PCV3 from wild boar to domestic pigs was demonstrated in Italy". Shedding is by "oral fluids, nasal secretions, and feces"; "VERTICAL TRANSMISSION CAN ALSO OCCUR and PCV3 in colostrum may contribute to vertical transmission"; and "despite the limited data on PCV3, ITS WIDESPREAD NATURE SUGGESTS EFFECTIVE HORIZONTAL AND VERTICAL TRANSMISSION". Infection is long: viral DNA was detected repeatedly in individual pigs on Spanish farms "for periods of 12-20 weeks", and in recaptured wild boar "over a period of 5-7 months". shic_2026_pcv3: "PCV3 is found in wild and domestic pigs in many swine-producing regions of the world." "Globally, PCV3 prevalence ranges from about 6.5% to 84%." "In 2016, PCV3 was detected in tissues from sows from North Carolina." "Evidence suggests that PCVs have been circulating in swine long before they were first detected." "Circoviruses are stable in the environment."
How this level was decided
Level 2 would need housing to close a route, and there is no route to close: PCV3 is worldwide in healthy and diseased pigs, passes from sow to piglet in colostrum, and persists in individuals for three to five months. Level 1 -- present in most herds and carried by the pigs themselves, so there is no introduction event to prevent. NOTE THE FERAL SWINE FINDING AND WHY IT DOES NOT RAISE THE LEVEL: PCV3 is commonest of the three circoviruses in feral swine and transmission from wild boar to domestic pigs has been demonstrated, which under the OLD reservoir framing would have argued for a high level. Under the exclusion framing settled on 2026-09-03 it is irrelevant, because the virus is already inside the herd the feral pigs would be introducing it to. Level 1 confirmed and now firmly supported: prevalence up to 84%, present in US herds since at least 2016, and circulating undetected long before that. No introduction event to prevent.
C4 Detection difficulty
Difficulty of recognizing and confirming infection
Laboratory-dependent: The presentation does not point to this disease specifically, but local or regional laboratories can confirm it with a validated assay once it is suspected
CONFIRMED by Eric. The assignment reached this level from the evidence, and he has reviewed and ratified it.
Confirmed by Eric. CONFIRMED. "c4l2, reliance is on non-commercial kit PCR but the agent has been around long enough, and studied by the US research community, that reliable primers are available. Some argument could be made for l3 but we will hold at l2 for now"
Basis. ch27 27.5.5.1: "Research on the pathogenesis of PCV3 has been slowed by the LIMITED AVAILABILITY OF VIRUS ISOLATES, LACK OF PCV3 ANTIBODY- AND VIRUS-FREE PIGS, and the ubiquitous distribution of the virus. WITH THE EXCEPTION OF SEVERAL PCR METHODS, FEW REAGENTS HAVE BEEN GENERATED FOR LABORATORY USE." 27.5.5.3 sets the diagnostic bar for disease rather than infection: late-term abortions and stillbirths or postweaning wasting, PLUS systemic nonsuppurative arteritis and periarteritis, PLUS moderate-to-high amounts of PCV3 in those vascular lesions -- and "although qPCR correlates with ISH results in tissues, THE DETECTION OF VIRAL GENOME WITHIN LESIONS BY ISH IS THE DEFINITIVE DIAGNOSTIC CRITERIA for PCV3-AD". 27.5.5.2 states the reason: "the detection of an endemic virus by PCR methods in tissues or other biological samples IS NOT SUFFICIENT TO ESTABLISH A CAUSAL ASSOCIATION with the clinical signs or lesions". shic_2026_pcv3: "Many polymerase chain reaction (PCR) assays have been developed for PCV3 in the research setting. Most are based on the Cap protein." "PCV3 has only recently been isolated in cell culture." "Although antibodies are not diagnostic for PCV3, a few enzyme-linked immunosorbent assays (ELISAs) have been described." "New diagnostic tools are needed for surveillance and detection of new PCV strains."
How this level was decided
Level 2, and the criterion is asking about recognising and confirming INFECTION, which is what settles it. Several PCR methods exist, qPCR correlates with in situ hybridisation, and detecting PCV3 in a pig is ordinary diagnostic laboratory work. The presentation points nowhere -- the chapter lists respiratory disease, digestive disorders, congenital tremors, rectal prolapse, reproductive problems, multisystemic inflammation and healthy animals as contexts PCV3 has been found in -- which is the level 2 label. FLAGGED AS A LEVEL 2 OR 3 JUDGMENT because confirming DISEASE is a different and much harder thing: the definitive criterion is viral genome inside a vascular lesion by ISH, and the chapter says few reagents beyond PCR exist. If the criterion is read as the difficulty of reaching a diagnosis rather than a detection, this is level 3. Level 2 held. Detection itself is straightforward -- PCR is widely available and oral and processing fluids work for prevalence surveys. What the factsheet flags is a harder problem that C4 does not measure: because infection is often subclinical and co-infection common, a positive PCR does not establish causation. That is an interpretation difficulty, not a detection one.
C5 Production cost
Financial impact on the infected farm's cost of production
Minor: Small and generally short-lived losses with little effect on overall cost of production
CONFIRMED by Eric. The assignment reached this level from the evidence, and he has reviewed and ratified it.
Confirmed by Eric. CONFIRMED. "c5l2, this is an acceptable rating for now as evidence is not clear about overall prevalence and clinical significance relative to PCV2 which is very well characterized"
Basis. ch27 27.1: "PCV3 IS CONSIDERED PATHOGENIC and case definitions for PCV3-reproductive disease and PCV3-systemic disease have been proposed." 27.5.5.2: "a more consistent association of PCV3 infection has been established with REPRODUCTIVE DISORDERS and, to a lesser extent, with WASTING IN POSTWEANING PIGS affected by systemic inflammation", with systemic nonsuppurative arteritis and periarteritis, myocarditis, interstitial pneumonia and interstitial nephritis. The strongest causal evidence is experimental: pregnant gilts inoculated at different stages of gestation gave "HIGH VIRAL LOADS... IN FETAL TISSUES IN ASSOCIATION WITH CHARACTERISTIC HISTOLOGICAL LESIONS, thus demonstrating that PCV3 CAN CAUSE TRANSPLACENTAL INFECTION AND LESIONS IN FETUSES". Against that, 27.5.5.1: "to date, PCV3 experimental infection studies (all in nursery pigs) have reported SUBCLINICAL INFECTIONS or a PDNS-like condition", the virus is found "in healthy animals of different ages", and its "pathogenesis and clinical significance are still under debate". No morbidity, mortality or cost figure appears anywhere. shic_2026_pcv3: "PCV3 has been associated with respiratory disease, reproductive failure, neurological disease, enteric disease, and porcine dermatitis and nephropathy syndrome (PDNS)." "In pathogenicity studies, PCV3 inoculation does not consistently lead to the development of clinical disease." "Death is uncommon in young pigs, but perinatal mortality in sows is a feature of reproductive disease." "It remains unclear whether PCV3 is a primary pathogen."
How this level was decided
Level 2, and FLAGGED AS THE JUDGMENT MOST WORTH ERIC'S EYE IN THIS BATCH because the chapter gives nothing to size it with. What is established is that PCV3 causes disease -- the pregnant gilt study is a clean demonstration of transplacental infection producing fetal lesions, and case definitions exist for two syndromes. What is not established is how much: every nursery-pig inoculation produced subclinical infection, the virus is as common in healthy pigs as in sick ones, and there is no prevalence of disease and no cost figure in the chapter at all. Level 2 records small and generally short-lived losses on the strength of a demonstrated but unquantified reproductive effect. IT IS NOT LEVEL 1, because unlike porcine norovirus this agent has been shown to cause lesions; and it is not level 3, because nothing supports a claim that the losses measurably increase cost of production. Level 2 held, and the January 2026 update leaves the central question open in the same place it has been: the syndrome list is long, but pathogenicity studies are inconsistent and it is still unclear whether PCV3 is a primary pathogen at all.
C6 Market impact
Duration of material disruption to pork and pig markets
Negligible: Little or no material disruption to supply or demand when disease occurs on one or more farms
CONFIRMED by Eric. The assignment reached this level from the evidence, and he has reviewed and ratified it.
Confirmed by Eric. CONFIRMED. "c6l1, market is already well aware of disease presence on it has had no impact"
Basis. A virus detected worldwide in healthy and diseased pigs since 2016, present in US herds and in feral swine. No trade measure, movement control or consumer response is recorded anywhere in chapter 27. shic_2026_pcv3: "PCV3 is found in wild and domestic pigs in many swine-producing regions of the world." Prevalence to 84%, present in the US since 2016 with no market event recorded.
How this level was decided
INFERRED. Under the standing note SCORING/market_impact, an agent already endemic in US pigs and diagnosed routinely with no market move on record is level 1. PCV3 has been detected and reported in the United States since 2016 and nothing has followed. Level 1 confirmed -- the endemic, already-diagnosed case in the standing note, where the absence of any historical market move is the evidence.
C7 Treatment potential
Potential for treatment to improve outcomes
Little: Effective pathogen-directed treatment is available and works, or animals recover acceptably without it
CONFIRMED by Eric. The assignment reached this level from the evidence, and he has reviewed and ratified it.
Confirmed by Eric. CONFIRMED. "c7l1, trying to stay consistent with other similar situations and agents."
Basis. No treatment for PCV3 is described anywhere in chapter 27. 27.7: management of cofactors along the lines of Madec's 20-point plan is "THE ONLY APPROACH TO CONTROL PCV3-INDUCED (AND POTENTIALLY PCV4-INDUCED) DISEASE AS NO VACCINES ARE AVAILABLE FOR THESE TWO VIRUSES." 27.5.5.1, on where the damage occurs: pregnant gilts inoculated before fetal immunocompetence produced piglets with lesions detectable at birth, and "these results suggested that POSTNATAL DISEASE COULD BE CAUSED BY INTRAUTERINE INFECTIONS", with PCV3-SD possibly "the postnatal consequence of PCV3-RD". shic_2026_pcv3: "There is no treatment for pigs infected with PCV3."
How this level was decided
Level 1, on the transplacental boundary Eric drew on 2026-09-02. His rule says C7 scores the value of a treatment that does not exist rather than the industry's willingness to use one, but it carries an explicit exception: LEVEL 1 STILL HOLDS WHERE THE HARM IS TRANSPLACENTAL AND COMPLETE BEFORE BIRTH, because no treatment could act in any window -- Getah virus, the pestiviruses and Japanese encephalitis virus sit there for that reason. The chapter's own conclusion puts PCV3 in that category: the reproductive disease is intrauterine, and the postweaning systemic disease may be its consequence rather than a separate event. FLAGGED LIGHTLY, because that conclusion is offered as a possibility rather than established, and if the postweaning wasting turns out to be a distinct postnatal disease there is a window and this cell moves to level 3. Level 1 held.
C8 Vaccine availability
Availability of effective vaccines or bacterins
Needed but not available: No effective vaccine is available in the US or has been developed, and the disease would justify vaccinating if one existed
CONFIRMED by Eric. The assignment reached this level from the evidence, and he has reviewed and ratified it.
Confirmed by Eric. CONFIRMED. "c8l3, general belief is that the agent is causing clinical diseasae and that vaccination would be warranted in at least some situations"
Basis. ch27 27.7, stated as a limitation on control rather than as an aside: management of environmental and infectious cofactors is "THE ONLY APPROACH TO CONTROL PCV3-INDUCED (and potentially PCV4-induced) DISEASE AS NO VACCINES ARE AVAILABLE FOR THESE TWO VIRUSES." 27.2.2: "based on sequencing data, NO OR VERY LIMITED CROSS-PROTECTION IS EXPECTED BETWEEN PCV2 AND PCV3 OR PCV4", so the near-universal PCV2 vaccination does nothing here. 27.1: "PCV3 is considered pathogenic and case definitions for PCV3-reproductive disease and PCV3-systemic disease have been proposed." shic_2026_pcv3: "There is no cross-protection between PCV3 and other PCVs, including PCV2. There are no commercially available PCV3 vaccines, but vaccination is available through a veterinary prescription."
How this level was decided
Level 3, and FLAGGED AS A LEVEL 1 OR 3 JUDGMENT. There is certainly no vaccine, so the question is entirely whether the disease would justify one. THE CASE FOR LEVEL 3, which is scored: the chapter frames the absence as a gap rather than an absence of need -- cofactor management is "the only approach" BECAUSE no vaccine exists -- PCV3 is called pathogenic, two syndromes have agreed case definitions, and the PCV2 vaccine the industry already gives every pig confers no cross-protection. THE CASE FOR LEVEL 1 is that the clinical significance is still under debate and every nursery inoculation study produced subclinical infection, so a product might be built for a disease that turns out not to matter. This cell moves with C5. LEVEL 3 HELD, AND FLAGGED as the one genuinely new fact in this update. Autogenous or prescription PCV3 vaccination is now available, and the standing note says autogenous product COUNTS AS AVAILABLE -- that is the actinobacillus_suis and streptococcus_beta_hemolytic precedent, herds paying to make and give a bacterin of unquantified effect, scored level 2. On that reading this cell is a 2. I have held it at 3 because the note's level 2 examples are products herds routinely buy, whereas this is a prescription route for a pathogen whose primary role is still unproven, and moving it would be a level change on a single new clause. Eric decides.
Levels and evidence are generated from data/assignments/pcv3.yml; the overview is authored in data/overviews/pcv3.md. Do not hand-edit this page — corrections go in data/assignments/CORRECTIONS.yml.
Quoted material marked Basis is from Zimmerman JJ, Karriker LA, Ramirez A, Schwartz KJ, Stevenson GW, Zhang J, eds. Diseases of Swine, 12th edition. Hoboken: Wiley Blackwell, 2025 — except where another source is named in the quotation itself.